Navigation Links
Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference
Date:11/23/2014

HAYWARD, Calif., Nov. 23, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), announced today that Paul F. Truex, President and Chief Executive Officer, will present a corporate update at the 2014 Annual Piper Jaffray Healthcare Conference.

Anthera will present at 4:30PM ET, December 3rd, at the Palace Hotel in New York City.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2013.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com or 510.856.5598.

 


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
5. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
6. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
7. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
10. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
11. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2019)... ... March 20, 2019 , ... Latitude is the new ... administration firm specializing in quality retirement plan administration, Latitude has offices nationally and ... is as much an idea as it is a destination. It reflects our ...
(Date:3/20/2019)... ... March 20, 2019 , ... Dr. Jason Tucker founded ... stem cells for treating acute and chronic injuries such as arthritis, joint, ligament and ... a wide range of patients from NBA & NFL athletes to weekend warriors to ...
(Date:3/20/2019)... N.J. (PRWEB) , ... March 20, 2019 , ... ... that Greek American Rehabilitation & Care Centre used its SmartLinx suite to refute ... Services (CMS) regulations. , When the Illinois Department of Public Health regulators alleged ...
Breaking Medicine Technology:
(Date:3/20/2019)... ... ... Vera Whole Health , a national leader in advanced primary care, ... employees healthy and drive down the total cost of care. This white paper is ... clinics. , The Vera white paper covers several topics including:, ...
(Date:3/20/2019)... ... March 20, 2019 , ... Dr. Joe Lowrance, psychologist ... for financial consultants: “Learn to practice mindfulness.” , In a white paper, ... Dr. Lowrance writes that financial advisors are discovering the power of mindfulness as ...
(Date:3/20/2019)... ... March 20, 2019 , ... ... today the launch of its mSource® Predictive Plan, a new analytics feature that ... It gives purchased services teams the control to develop a customized purchasing roadmap ...
(Date:3/20/2019)... ... March 20, 2019 , ... Nike Softball Camp ... Slupinski will be leading the camp with her staff. , Coach Slupinski takes the ... Redlands where she was the head coach for 2 seasons. Slupinski had an impressive ...
(Date:3/20/2019)... ... , ... Dr. Samuel Lin, board-certified Nose Expert representing the ... Network, well known for their exclusivity, and luxurious lifestyle is privileged to present ... to the Haute Living partnership. , Haute Beauty offers a prominent collective of ...
Breaking Medicine News(10 mins):